This produces a signal when it attaches to a blood clot and the patient is put through an imaging machine.
Physicians then have clear idea of the location and size of the blood clot.
Animal studies are currently underway at the University of California San Diego to identify suitable clone candidates to produce the humanised antibody for the project. The completion for these studies is expected in January 2001. Assuming a successful outcome, AGEN this month concluded an agreement with Dr Paul Eisenberg, a US specialist in cardiovascular medicine, to advise on the project. Effective clinical trial design and management is also crucial to the project. Under an agreement with Agen earlier this month, Kendle Pty Ltd a Melbourne-based clinical research organisation, is preparing a development plan for advancement of the project.